News for Compugen Ltd. (CGEN.TA)

Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's First Quarter 2025 Results Conference Call. At this time, all participants are in listen-only mode.

Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ETCompany ParticipantsYvonne Naughton - VP, Head of IR & Corporate...

PR NewswireHOLON, Israel, May 19, 2025 Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025

Compugen (CGEN) initiated a trial for COM701 therapy in ovarian cancer and continues recruitment for the GS-0321 Phase 1 trial. AstraZeneca expanded ril

\n\nPR NewswireHOLON, Israel, May 5, 2025\n\n\n\nHOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunot

\n Compugen Ltd. (CGEN) will release its Q1 2025 financial results on May 19, 2025, before U.S. markets open. A conference call and webcast will be held at

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Compugen Ltd.

Penny stocks trade below $5 and attract investors looking for high returns with a small initial investment.

Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Fourth Quarter and Full Year 2024 Results Conference Call.

Mar 04, 2025 / 01:30PM GMTOperator Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's fourth-quarter and full-year 2024 results confere

Compugen Ltd. (NASDAQ:CGEN) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ETCompany ParticipantsYvonne Naughton - VP, Head of IR and Corporate...

PR NewswireHOLON, Israel, March 4, 2025 In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd

PR NewswireHOLON, Israel, March 4, 2025 Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG an

PR NewswireHOLON, ISRAEL, March 3, 2025 HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer im

PR NewswireHOLON, Israel, Feb. 26, 2025 Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Un

PR NewswireHOLON, Israel, Feb. 18, 2025 HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immu

This is our list of the best penny stocks to watch, based on a review of stocks that had positive performance over the last 30 days.

Compugen Ltd (CGEN), a clinical-stage therapeutic discovery and development company, saw its stock rise by 5% to $1.66 with a trading volume of 315,350 shares.

PR NewswireHOLON, Israel, Nov. 27, 2024 Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT